Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK.
BMC Gastroenterol. 2010 Oct 22;10:124. doi: 10.1186/1471-230X-10-124.
The paucity of controlled data for the treatment of most biliary sphincter of Oddi disorder (SOD) types and the incomplete response to therapy seen in clinical practice and several trials has generated controversy as to the best course of management of these patients. In this observational study we aimed to assess the outcome of patients with biliary SOD managed without sphincter of Oddi manometry.
Fifty-nine patients with biliary SOD (14% type I, 51% type II, 35% type III) were prospectively enrolled. All patients with a dilated common bile duct were offered endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy whereas all others were offered medical treatment alone. Patients were followed up for a median of 15 months and were assessed clinically for response to treatment.
At follow-up 15.3% of patients reported complete symptom resolution, 59.3% improvement, 22% unchanged symptoms, and 3.4% deterioration. Fifty-one percent experienced symptom resolution/improvement on medical treatment only, 12% after sphincterotomy, and 10% after both medical treatment/sphincterotomy. Twenty percent experienced at least one recurrence of symptoms after initial response to medical and/or endoscopic treatment. Fifty ERCP procedures were performed in 24 patients with an 18% complication rate (16% post-ERCP pancreatitis). The majority of complications occurred in the first ERCP these patients had. Most complications were mild and treated conservatively. Age, gender, comorbidity, SOD type, dilated common bile duct, presence of intact gallbladder, or opiate use were not related to the effect of treatment at the end of follow-up (p > 0.05 for all).
Patients with biliary SOD may be managed with a combination of endoscopic sphincterotomy (performed in those with dilated common bile duct) and medical therapy without manometry. The results of this approach with regards to symptomatic relief and ERCP complication rate are comparable to those previously published in the literature in cohorts of patients assessed by manometry.
大多数胆胰管Oddi 括约肌功能障碍(SOD)类型的治疗缺乏对照数据,以及临床实践和几项试验中观察到的治疗不完全反应,这引发了关于这些患者最佳治疗管理的争议。在这项观察性研究中,我们旨在评估未经 Oddi 括约肌测压术治疗的胆胰管 SOD 患者的结局。
前瞻性纳入 59 例胆胰管 SOD 患者(14%为 I 型,51%为 II 型,35%为 III 型)。所有胆总管扩张的患者均行内镜逆行胰胆管造影术(ERCP)和括约肌切开术,而其他患者仅行药物治疗。患者中位随访 15 个月,并进行临床评估以判断治疗反应。
随访时,15.3%的患者报告完全症状缓解,59.3%的患者症状改善,22%的患者症状无变化,3.4%的患者症状恶化。51%的患者仅接受药物治疗即可缓解/改善症状,12%的患者接受括约肌切开术,10%的患者接受药物和括约肌切开术。20%的患者在初始药物和/或内镜治疗后至少有一次症状复发。24 例患者共行 51 次 ERCP 操作,并发症发生率为 18%(16%为 ERCP 后胰腺炎)。大多数并发症发生在首次 ERCP 的这些患者中。大多数并发症为轻度且经保守治疗。年龄、性别、合并症、SOD 类型、胆总管扩张、胆囊完整、或使用阿片类药物与随访结束时的治疗效果无关(p>0.05)。
胆胰管 SOD 患者可采用内镜括约肌切开术(适用于胆总管扩张的患者)联合药物治疗,无需测压术。与以前文献中通过测压术评估的患者队列相比,这种方法在缓解症状和 ERCP 并发症发生率方面的结果相当。